Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$5.22M-53.88%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Andre Choulika
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 229
- Beta
- 2.92
- Country
- FR
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1.25
Financials
Revenue
$5.22M-53.9%Net Income
$-21.79MEBITDA
$-21.04MFree Cash Flow
$-14.54MEPS (diluted)
$-0.22Shares Outstanding (diluted)
100.65M+181.8%Operating Expenses
$26.27MCash & Debt
$166.85MReturn of Capital
$0.00Revenue by Segment (annual)
$25.73MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $72.95M | $-67.59M | $-0.68 |
| 2024 | $41.51M | $-36.76M | $-0.41 |
| 2023 | $755.0K | $-101.06M | $-1.77 |
| 2022 | $19.17M | $-106.14M | $-2.33 |
| 2021 | $30.35M | $-114.20M | $-2.69 |
| 2020 | $51.06M | $-81.07M | $-1.71 |
| 2019 | $15.19M | $-102.09M | $-2.14 |
| 2018 | $12.73M | $-78.69M | $-1.93 |
| 2017 | $25.19M | $-99.37M | $-2.78 |
| 2016 | $42.58M | $-63.92M | $-1.81 |
| 2015 | $55.04M | $-22.46M | $-0.66 |
| 2014 | $26.30M | $24.3K | $0.00 |
| 2013 | $22.82M | $-84.28M | $-4.08 |
| 2012 | $27.81M | $-29.45M | $-1.48 |
Valuation
CLLShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
110+10.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·5h ago·Positive
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a pioneer in gene editing, announced that on September 11, 2026, the board of directors approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases.
View source ↗ - Newsglobenewswire.com·2d ago·Neutral
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update.
View source ↗
Earnings
Fri, Nov 13(in 2 months)
Consensus estimate $-0.20 per share
Typical surprise +5.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.22 vs $-0.26beat
- Mon, May 11$-0.18 vs $-0.26beat
- Thu, Mar 19$-0.26 vs $-0.20miss
- Fri, Nov 7$0.01 vs $-0.10beat
- Mon, Aug 4$-0.24 vs $-0.10miss
- Mon, May 12$-0.18 vs $-0.19beat
Estimates and results for CLLS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in CLLS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.